Premium
The challenge of drug approval in rare cancers
Author(s) -
Kasper Bernd
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33314
Subject(s) - medicine , drug approval , population , intensive care medicine , drug , family medicine , surgery , pharmacology , environmental health
Pexidartinib has emerged as a promising treatment option for patients with advanced tenosynovial giant cell tumors and could demonstrate encouraging long‐term control in this patient population. This editorial aims to pick out as a central theme the complex and somehow unfortunate registration status of pexidartinib in Europe in comparison with the United States.